Sirtuin Deacetylases: a New Target for Melanoma Management

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2014 Dec 9

PMID 25486469

Citations 21

Authors

Melissa J Wilking

Chandra K Singh

Minakshi Nihal

Mary A Ndiaye

Nihal Ahmad

Affiliations

Soon will be listed here.

Abstract

Melanoma continues to cause more deaths than any other skin cancer, necessitating the development of new avenues of treatment. One promising new opportunity comes in the form of mechanism-based therapeutic targets. We recently reported the overexpression and delocalization of the class III histone deacetylase SIRT1 in melanoma, and demonstrated that its small molecule inhibition via Tenovin-1 decreased cell growth and viability of melanoma cells, possibly by a p53 mediated induction of p21. Here, we support our data using additional SIRT inhibitors, viz. Sirtinol and Ex-527, which suggests possible benefits of concomitantly inhibiting more than one Sirtuin for an effective cancer management strategy. This "Extra View" paper also includes a discussion of our results in the context of similar recent and concurrent studies. Furthermore, we expand upon our findings in an analysis of new research that may link the cellular localization and growth effects of SIRT1 with the PI3K signaling pathway.

Citing Articles

Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.

Wawruszak A, Luszczki J, Bartuzi D, Kalafut J, Okon E, Czerwonka A J Enzyme Inhib Med Chem. 2025; 40(1):2458554.

PMID: 39935420 PMC: 11823383. DOI: 10.1080/14756366.2025.2458554.

Melanoma Metabolism: Molecular Mechanisms and Therapeutic Implications in Cutaneous Oncology.

J Tan I, Parikh A, Cohen B Cancer Med. 2024; 13(21):e70386.

PMID: 39494561 PMC: 11532834. DOI: 10.1002/cam4.70386.

Extracellular matrix stiffness controls cardiac valve myofibroblast activation through epigenetic remodeling.

Walker C, Batan D, Bishop C, Ramirez D, Aguado B, Schroeder M Bioeng Transl Med. 2022; 7(3):e10394.

PMID: 36176599 PMC: 9472021. DOI: 10.1002/btm2.10394.

Tenovin-1 Ameliorates Renal Fibrosis in High-Fat-Diet-Induced Diabetic Nephropathy via Antioxidant and Anti-Inflammatory Pathways.

Kundu A, Gali S, Sharma S, Park J, Kyung S, Kacew S Antioxidants (Basel). 2022; 11(9).

PMID: 36139886 PMC: 9495519. DOI: 10.3390/antiox11091812.

Emerging Roles of Post-Translational Modifications in Skin Diseases: Current Knowledge, Challenges and Future Perspectives.

Yang L, Yan Y J Inflamm Res. 2022; 15:965-975.

PMID: 35177923 PMC: 8846607. DOI: 10.2147/JIR.S339296.

References

Allison S, Milner J . SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle. 2007; 6(21):2669-77. DOI: 10.4161/cc.6.21.4866. View

Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y . Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. 2007; 282(9):6823-32. DOI: 10.1074/jbc.M609554200. View

Bouras T, Fu M, Sauve A, Wang F, Quong A, Perkins N . SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem. 2005; 280(11):10264-76. DOI: 10.1074/jbc.M408748200. View

Bhatia S, Tykodi S, Thompson J . Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009; 23(6):488-96. PMC: 2737459. View

Inoue T, Hiratsuka M, Osaki M, Oshimura M . The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle. 2007; 6(9):1011-8. DOI: 10.4161/cc.6.9.4219. View

Singh C, George J, Nihal M, Sabat G, Kumar R, Ahmad N . Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach. Oncotarget. 2014; 5(7):1987-99. PMC: 4039116. DOI: 10.18632/oncotarget.1898. View

Stunkel W, Campbell R . Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011; 16(10):1153-69. DOI: 10.1177/1087057111422103. View

Byles V, Chmilewski L, Wang J, Zhu L, Forman L, Faller D . Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci. 2010; 6(6):599-612. PMC: 2952410. DOI: 10.7150/ijbs.6.599. View

Grozinger C, Chao E, Blackwell H, Moazed D, Schreiber S . Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001; 276(42):38837-43. DOI: 10.1074/jbc.M106779200. View

10.

Han Y, Jin Y, Kim Y, Kang B, Choi H, Kim D . Acetylation of Sirt2 by p300 attenuates its deacetylase activity. Biochem Biophys Res Commun. 2008; 375(4):576-80. DOI: 10.1016/j.bbrc.2008.08.042. View

11.

Klinac D, Gray E, Millward M, Ziman M . Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013; 3:54. PMC: 3601325. DOI: 10.3389/fonc.2013.00054. View

12.

Ohanna M, Bonet C, Bille K, Allegra M, Davidson I, Bahadoran P . SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. Oncotarget. 2014; 5(8):2085-95. PMC: 4039147. DOI: 10.18632/oncotarget.1791. View

13.

Wilking M, Singh C, Nihal M, Zhong W, Ahmad N . SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys. 2014; 563:94-100. PMC: 4201895. DOI: 10.1016/j.abb.2014.04.001. View

14.

Napper A, Hixon J, McDonagh T, Keavey K, Pons J, Barker J . Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005; 48(25):8045-54. DOI: 10.1021/jm050522v. View

15.

Lain S, Hollick J, Campbell J, Staples O, Higgins M, Aoubala M . Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008; 13(5):454-63. PMC: 2742717. DOI: 10.1016/j.ccr.2008.03.004. View

16.

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

17.

Chakraborty R, Wieland C, Comfere N . Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med. 2013; 6:49-56. PMC: 3702032. DOI: 10.2147/PGPM.S44800. View

18.

Khaled M, Larribere L, Bille K, Ortonne J, Ballotti R, Bertolotto C . Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. J Invest Dermatol. 2003; 121(4):831-6. DOI: 10.1046/j.1523-1747.2003.12420.x. View

19.

Porta C, Paglino C, Mosca A . Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014; 4:64. PMC: 3995050. DOI: 10.3389/fonc.2014.00064. View

20.

Kunimoto R, Jimbow K, Tanimura A, Sato M, Horimoto K, Hayashi T . SIRT1 regulates lamellipodium extension and migration of melanoma cells. J Invest Dermatol. 2014; 134(6):1693-1700. DOI: 10.1038/jid.2014.50. View